Analyzing Prima BioMed (NASDAQ:IMMP) & Orchestra BioMed (NASDAQ:OBIO)

Orchestra BioMed (NASDAQ:OBIO) and Prima BioMed (NASDAQ:IMMP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.

Insider and Institutional Ownership

53.2% of Orchestra BioMed shares are held by institutional investors. Comparatively, 2.3% of Prima BioMed shares are held by institutional investors. 8.1% of Orchestra BioMed shares are held by company insiders. Comparatively, 3.1% of Prima BioMed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Orchestra BioMed has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. Comparatively, Prima BioMed has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500.

Profitability

This table compares Orchestra BioMed and Prima BioMed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-2,665.05%	-320.09%	-106.20%
Prima BioMed	N/A	N/A	N/A

Valuation & Earnings

This table compares Orchestra BioMed and Prima BioMed”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchestra BioMed	$2.64 million	90.27	-$61.02 million	($1.82)	-2.32
Prima BioMed	$6.69 million	64.76	-$39.78 million	N/A	N/A

Prima BioMed has higher revenue and earnings than Orchestra BioMed.

Analyst Ratings

This is a summary of current ratings and price targets for Orchestra BioMed and Prima BioMed, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	1	1	5	1	2.75
Prima BioMed	1	0	0	0	1.00

Orchestra BioMed presently has a consensus price target of $13.80, indicating a potential upside of 227.01%. Given Orchestra BioMed’s stronger consensus rating and higher probable upside, analysts plainly believe Orchestra BioMed is more favorable than Prima BioMed.

Summary

Orchestra BioMed beats Prima BioMed on 7 of the 13 factors compared between the two stocks.

About Orchestra BioMed

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

About Prima BioMed

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.